Prosecution Insights
Prosecution Insights
11 pending office actions • 5 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 5 (45%) |
| No statute on record | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 2 | 63.7% | +39.7% |
| CHASE, CAROL ANN | 1 | 44.6% | +83.5% |
| NICKOL, GARY B | 1 | 43.9% | +26.4% |
| GODDARD, LAURA B | 1 | 50.7% | +14.6% |
| DARPOLOR, JOSEPHINE KEBBEH | 1 | 61.5% | +41.7% |
| MOSELEY II, NELSON B | 1 | 68.1% | +41.7% |
| SHUPE, ELIZABETH A | 1 | 63.3% | +49.1% |
| MIDDLETON, DANAYA L | 1 | 43.5% | +53.4% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 60.1% | +25.4% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.6% | +42.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | NICKOL, GARY B | 23d overdue |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 6d |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | MOSELEY II, NELSON B | 22d |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 27d |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | MIDDLETON, DANAYA L | 28d |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | SHUPE, ELIZABETH A | 29d |
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | CHASE, CAROL ANN | 42d |
| Art Unit | Apps |
|---|---|
| 1643 | 4 |
| 1642 | 3 |
| 1646 | 2 |
| 1674 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | CHASE, CAROL ANN | 1646 | Other | Final Rejection | 42d | Pending | Jan 22, 2024 |
| 18257528 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | NICKOL, GARY B | 1643 | Other | Non-Final OA | 23d overdue | Pending | Jun 14, 2023 |
| 18251832 | MEANS AND METHODS FOR TREATING SUBJECTS WITH ERBB3 MUTATION POSITIVE CANCER | GODDARD, LAURA B | 1642 | §103 | Non-Final OA | 6d | Pending | May 04, 2023 |
| 18084797 | BINDING DOMAINS AGAINST CANCER-ASSOCIATED MUC1 | DARPOLOR, JOSEPHINE KEBBEH | 1642 | Other | Non-Final OA | 69d | Pending | Dec 20, 2022 |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | MOSELEY II, NELSON B | 1642 | §112 | Non-Final OA | 22d | Pending | Dec 07, 2022 |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | 27d | Pending | Nov 18, 2022 |
| 17921042 | TREATMENT OF CANCERS WITH AN ANTIBODY THAT BINDS LGR5 AND EGFR | SHUPE, ELIZABETH A | 1643 | §112 | Final Rejection | 29d | Pending | Oct 24, 2022 |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 70d | Pending | Apr 22, 2022 |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | MIDDLETON, DANAYA L | 1674 | Other | Final Rejection | 28d | Pending | Feb 01, 2022 |
| 17431044 | COMBINATIONS OF BINDING MOIETIES THAT BIND EGFR, HER2 AND HER3 | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 30d overdue | Pending | Aug 13, 2021 |
| 16906531 | ANTIBODY PRODUCING NON-HUMAN ANIMALS | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | 55d | Pending | Jun 19, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial